FOXO TECHNOLOGIES INC. Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Continuing Operations
FOXO TECHNOLOGIES INC. (FOXO) reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Continuing Operations of -$1.83 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2025-08-19.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectContinuingOperations · last filed 2025-08-19
- FOXO TECHNOLOGIES INC. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect continuing operations for the quarter ending 2024-03-31 was -$406.30K.
| Period end | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Continuing Operations 3 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Continuing Operations 6 month |
|---|---|---|
| 2024-06-30 | -$1.83M 10-Q · filed 2025-08-19 | |
| 2024-03-31 | -$406.30K 10-Q/A · filed 2025-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |